Skip to Main Content
TABLE 3

The risk of death from and hospitalization for renal and cardiovascular events, evaluated using the pooled logistic regression analysis

Crude risk (95% CI)Adjusted risk (95% CI)
Model 1Model 2
Reduction of albuminuria    
    50% reduction 0.38 (0.16–0.91) 0.47 (0.17–0.98) 0.41 (0.15–0.96) 
    Nonreduction 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
Stage of diabetic nephropathy    
    Remission 0.30 (0.09–0.98) 0.27 (0.08–0.91) 0.25 (0.07–0.87) 
    No change 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
    Progression 2.31 (1.06–5.07) 2.45 (1.06–5.65) 2.55 (1.04–6.30) 
Crude risk (95% CI)Adjusted risk (95% CI)
Model 1Model 2
Reduction of albuminuria    
    50% reduction 0.38 (0.16–0.91) 0.47 (0.17–0.98) 0.41 (0.15–0.96) 
    Nonreduction 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
Stage of diabetic nephropathy    
    Remission 0.30 (0.09–0.98) 0.27 (0.08–0.91) 0.25 (0.07–0.87) 
    No change 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
    Progression 2.31 (1.06–5.07) 2.45 (1.06–5.65) 2.55 (1.04–6.30) 

Model 1 adjusted for sex and age, initial AER levels, and a history of cardiovascular disease. Model 2 adjusted for sex, age, initial AER levels, a history of cardiovascular disease, current smoking, A1C, total and HDL cholesterol, triglyceride, systolic and diastolic blood pressure, BMI, and the use of ACE inhibitors, angiotensin receptor blockers, or lipid lowering-drugs. ref., referent.

Close Modal

or Create an Account

Close Modal
Close Modal